Cat. No. 1610
Chemical Name: 3'-[(8-Cinnamoyl-5,7-dihydroxy-2,2-dimethyl-2H-1-benzopyran-6-yl)methyl]-2',4',6'-trihydroxy-5'-methylacetophenone
Biological ActivityOriginally reported to inhibit PKC isoforms. Also reported to inhibit CAM kinase III. However, recently shown to inhibit a wide range of protein kinases, and most potently to inhibit PRAK and MAPKAP-K2 (IC50 values are 1.9 and 5 μM respectively). Also shown to act as a direct mitochondrial uncoupler. Thought to stimulate autophagy by targeting upstream mTORC1 control pathways.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Gschwendt et al (1994) Rottlerin, a novel protein kinase inhibitor. Biochem.Biophys.Res.Commun. 199 93. PMID: 8123051.
Davies et al (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem.J. 351 95. PMID: 10998351.
Zhang et al (2007) Neuroprotective effect of protein kinase Cδ inhibitor rottlerin in cell culture and animal models of Parkinson's disease. J.Pharmacol.Exp.Ther. 322 913. PMID: 17565007.
Balgi et al (2009) Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS One 4 e7124. PMID: 19771169.
If you know of a relevant citation for this product please let us know.
Keywords: Rottlerin, supplier, Reported, PKCdelta, inhibitors, Protein, Kinases, C
Find multiple products by catalog number
New Products in this Area
STK33 inhibitorCRT 0066101
Potent protein kinase D (PKD) inhibitorHarmine
Potent and selective Dyrk1A inhibitorAZ 628
Potent Raf kinase inhibitorCHIR 99021 trihydrochloride
Hydrochloride salt of CHIR 99021 (Cat. No. 4423); selective GSK-3 inhibitorYZ9
PFKFB3 inhibitor; inhibits cell growthKU 0060648
Dual DNA-PK and PI 3-K inhibitorKB SRC 4
Potent and selective c-Src inhibitorProINDY
Dyrk1A/B inhibitor; prodrug of INDY (Cat. No. 4997)INDY
Dyrk1A/B inhibitorAZD 6482
Potent and selective PI 3-Kβ inhibitorAS 1892802
Potent ROCK inhibitor; orally bioavailableSC 79
Akt activatorSNS 314 mesylate
Potent pan-Aurora kinase inhibitorPD 180970
p210bcr/abl kinase inhibitor; also inhibits c-Src and KITPD 334581
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.